TY - JOUR
T1 - Clinical pathways for inborn errors of metabolism: warranted and feasible
AU - Demirdas, Serwet
AU - van Kessel, Imke N.
AU - Korndewal, Marjolein J.
AU - Hollak, Carla E. M.
AU - Meutgeert, Hanka
AU - Klaren, Anja
AU - van Rijn, Margreet
AU - van Spronsen, Francjan J.
AU - Bosch, Annet M.
AU - AUTHOR GROUP
AU - Asselbergs, Folkert W.
AU - Blank, Christiaan
AU - Derks, Terry G. J.
AU - Diekman, Eugène F.
AU - Dijsselhof, Monique E.
AU - Engelen, Marc
AU - van Hasselt, Peter M.
AU - ter Horst, Nienke M.
AU - van den Hurk, Dorine A. M.
AU - Janssen, Mirian C. H.
AU - Karstens, Francois P. J.
AU - van der Louw, Elles
AU - Morava, Eva
AU - Nicolai, Joost
AU - van de Pol, Ludo
AU - Poll-The, Bwee Tien
AU - Rubio-Gozalbo, Estela
AU - Smit, G. Peter A.
AU - de Ruijter, Jessica
AU - Timmer, Corrie
AU - Touw, Catharina M. L.
AU - Visser, Gepke
AU - de Valk, Harold W.
AU - Wijburg, Frits A.
AU - Williams, Monique
PY - 2013
Y1 - 2013
N2 - Inborn errors of metabolism (IEMs) are known for their low prevalence and multidisciplinary care mostly founded on expert opinion. Clinical pathways are multidisciplinary tools to organise care which provide a clear route to the best care and improve communication. In 2010 the Dutch Society for Children and Adults with an Inborn Error of Metabolism (VKS) initiated development of clinical pathways for inborn errors of metabolism. In this letter to the editor we describe why it is warranted to develop clinical pathways for IEMs and shortly discuss the process of development for these pathways in the Netherlands
AB - Inborn errors of metabolism (IEMs) are known for their low prevalence and multidisciplinary care mostly founded on expert opinion. Clinical pathways are multidisciplinary tools to organise care which provide a clear route to the best care and improve communication. In 2010 the Dutch Society for Children and Adults with an Inborn Error of Metabolism (VKS) initiated development of clinical pathways for inborn errors of metabolism. In this letter to the editor we describe why it is warranted to develop clinical pathways for IEMs and shortly discuss the process of development for these pathways in the Netherlands
U2 - https://doi.org/10.1186/1750-1172-8-37
DO - https://doi.org/10.1186/1750-1172-8-37
M3 - Comment/Letter to the editor
C2 - 23442887
SN - 1750-1172
VL - 8
SP - 37
JO - Orphanet Journal of Rare Diseases
JF - Orphanet Journal of Rare Diseases
IS - 1
ER -